The forecasted data indicate a steady increase in the number of multidrug-resistant tuberculosis (MDR-TB) cases started on treatment in Japan from 2024 to 2028, moving from 78 cases in 2024 to 87 cases in 2028. The year-on-year growth rate shows a consistent trend, with a reported low single-digit percentage growth expected annually. By 2028, the compound annual growth rate (CAGR) averages about 2.2% from 2023 levels, reflecting a gradual escalation in case starts likely due to heightened awareness and improved detection mechanisms.

Future trends to watch for include:

Advancements in medical technology contributing to more accurate and timely diagnosis of MDR-TB.
Government and health policy impacts that could influence resource allocation for MDR-TB programs.
A continued focus on public health strategies to curb the spread of tuberculosis in general, potentially affecting MDR-TB numbers.